Skip to main content

Security report for gene.com

Genentech · Healthcare · United States

Low risk. 1 critical or high finding in SSL/TLS.

Security score

86/100

Risk levelLow

0–100, higher is better. How it is calculated

Genentech is a leading biotechnology company specializing in biopharmaceutical research and development, serving healthcare professionals, patients, and investors. The website reflects a mature enterprise with consistent branding and comprehensive content focused on breakthrough science and patient care. Technically, the site employs modern JavaScript libraries, integrates Google Tag Manager for analytics, and uses OneTrust for cookie consent, indicating a strong digital maturity. Security posture is robust with HTTPS, security headers, and privacy compliance, though explicit security and incident response policies are not publicly detailed. Overall, the site is trustworthy and professionally maintained, with minor gaps in public security disclosures.

Scanned

NIS2 and GDPR posture

GDPR outside view
88/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

1 finding rated critical or high. Fix these first.

  1. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak SSL Key Length

      SSL certificate uses 256-bit key, which is considered weak

      What to do: Use at least 2048-bit RSA or 256-bit ECC key

      • CWE-326
      • OWASP A04:2025
      • Mozilla TLS: Mozilla Server Side TLS 6.0 intermediate: rsa_key_size 2048

Need hands-on remediation? Email guard@offseq.com

Keep watching gene.com

This scan found 12 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
75
Security headers
80
Email security
88
DNS health
85
Network security
100
GDPR outside view
88
Average
86

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Genentech operates in the healthcare and biotechnology sectors as a subsidiary of Roche, a global pharmaceutical leader. The business model centers on innovative drug development and patient support programs. The website targets a broad audience including healthcare professionals and patients, with clear market positioning as a top-tier biotech company. The presence of ISO certifications and strong privacy policies enhances credibility. The company leverages partnerships and maintains a strong digital presence, supporting growth and compliance in a regulated industry.

Security posture

The website demonstrates a good security maturity level with enforced HTTPS, comprehensive security headers, and a cookie consent mechanism compliant with GDPR. No vulnerabilities or exposed sensitive data were detected in the HTML content. However, the absence of a published security policy, incident response contact, and vulnerability disclosure program suggests room for improvement in transparency and readiness. The use of trusted third-party scripts is monitored, but continuous auditing is recommended to maintain security integrity.

Recommendations

  1. Publish a dedicated security policy page outlining security frameworks and practices.
  2. Provide clear incident response contact information to improve transparency.
  3. Implement and publicize a vulnerability disclosure policy and security.txt file.
  4. Regularly audit third-party scripts and libraries for vulnerabilities and updates.
  5. Enhance user trust by adding certifications and trust seals related to security and compliance.

Contact details published on the site

Addresses
Legal name
Genentech, Inc.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Genentech
Description
Breakthrough science. One moment, one day, one person at a time.
Key services
Biopharmaceutical research, Drug development, Patient support programs
Content quality
excellent
Branding
consistent

Technology

Stack
jQuery (custom queue), Alpine.js, Google Tag Manager, OneTrust Cookie Consent, CSS3, HTML5
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent mechanism
  • No exposed sensitive data in HTML
  • Use of security headers

Analytics and tracking

Services
Google Tag Manager
Tracking level
moderate
Privacy practices
good

Advertising

Marketing tools
OneTrust Cookie Consent
Transparency
good

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is professionally designed and well-structured.
  2. Strong privacy and cookie compliance with OneTrust integration.
  3. No signs of malicious or suspicious content.
  4. No visible security policy or incident response page.
  5. WHOIS data unavailable, possibly due to privacy protection.
  6. Use of modern JavaScript libraries and analytics tools.
  7. No adult or NSFW content detected.
  8. Clear branding consistent with Genentech and Roche.
Technical notes

Notes

The website uses a modern tech stack including jQuery, Alpine.js, and Google Tag Manager, supported by OneTrust for privacy compliance. The site is mobile optimized with responsive design and accessibility features. Performance is moderate, with room for optimization in loading speed. The absence of a detected CMS suggests a custom or proprietary platform. Hosting details are not explicit but the site uses secure HTTPS and standard web technologies. SEO and metadata are well implemented, supporting discoverability and user engagement.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with gene.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review gene.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.